A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine in Brazil
A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2
A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults
A Study of Ad26.COV2.S in Adults (COVID-19)
A Study of Ad26.COV2.S in Adults (COVID-19)
A Study of Ad26.COV2.S in Healthy Adults (COVID-19)
A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19)
A Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults and Adolescents
A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive
A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults
Ad26.COV2.S as a Heterologous Booster in Adults After Single- or Two-Dose of Inactivated COVID-19 Vaccine
Cohort Assessing the Immunogenicity and the Safety of the COVID-19 Vaccine Janssen in Healthy Volunteers Based on 2 Age Groups: 65 Years or Older - 55 to 65 Years. Covicompare-Janssen
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines
Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda
Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 Vaccine
Homologous vs Heterologous Third Vaccination in Kidney Transplant Recipients Kidney Transplant Recipients
Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients